SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
TNYA reported Third Quarter 2026 results. The price and volatility reaction is pending.
TNYAearnings

Earnings reactions, page 7

Tenaya Therapeutics, Inc. (TNYA) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Cash and cash equivalents were $66.8 million as of September 30, 2026.
  • Research & Development (R&D) expenses were $14.9 million for the third quarter of 2026.
  • Non-cash stock-based compensation included in R&D expense was $0.8 million for the third quarter of 2026.
  • General & Administrative (G&A) expenses were $5.6 million for the third quarter of 2026.
  • Non-cash stock-based compensation included in G&A expense was $0.9 million for the third quarter of 2026.
  • Net loss was $18.9 million, or $0.08 loss per share, for the third quarter ended September 30, 2026.

Guidance

  • Tenaya expects that cash and cash equivalents will be sufficient to fund planned operations into the fourth quarter of 2027.
  • Tenaya intends to initiate at least one company-sponsored Phase 2 clinical trial for TN-301 in the second half of 2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-04 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →